Depsipeptide compound
The present invention relates to a novel compound which is useful as an agent for prevention and treatment of diseases associated with HDAC, in particular, tumor or cell proliferative diseases. The depsipeptide compound or its pharmaceutically acceptable salt of the present invention has a good HDAC inhibitory activity and an inhibitory activity of cell proliferation against human cancer cells and, therefore, is useful in treatment and improvement of diseases and pathogenic conditions associated with histone acetylation, in particular, tumor or cell proliferative diseases.
1. An isolated depsipeptide compound of formula (I) or (II), or a pharmaceutically acceptable salt thereof:
2. An isomer of a depsipeptide compound having the planar structural formula represented by the formula (I) described in claim 1 and an optical rotation [α] 25 D of −349.3 degree (c 0.05, methanol solvent) or an isomer of a depsipeptide compound having the planar structural formula represented by the formula (II) described in claim 1 and an optical rotation [α] 25 D of −65.3 degree (c 0.20, methanol solvent), or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising the depsipeptide compound or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
4. A method for treating cancer, which comprises administering an effective amount of the depsipeptide compound or the pharmaceutically acceptable salt thereof according to claim 1 to a patient suffering from cancer.